Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Threshold Plummets As Merck Drops Evofosfamide For Sarcoma

This article was originally published in Scrip

Executive Summary

Threshold Pharmaceuticals saw its stock lose more than 80% of its value following disappointing data from two Phase III trials of its anticancer evofosfamide in advanced soft tissue sarcoma and advanced pancreatic adenocarcinoma. Its partner, Germany's Merck, said it would not be filing for approval of the product.

You may also be interested in...

Threshold And Molecular Templates Merge To Test The Power Of Two

Although a vehicle for Molecular Templates to take its Engineered Toxin Bodies oncology platform public, the combined company also will seek a pathway to approval for Threshold's evofosfamide for pancreatic cancer in Japan.

German Merck Identifies Pipeline Stars, Plots Course Through A Dynamic Cancer Space

As questions remain over Merck KGAA's ability to retain its top line following the patent loss for its key products Rebif and Erbitux, the German company has highlighted some of its higher priority R&D programs in its "very interesting" pipeline, as well as its strategy to make the most of the assets.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts